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Abstract
Background: Rituximab is effective as therapy for induction of remission in anti-neutrophil cytoplasmic antibody
(ANCA)-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse rates
are high, especially in patients with a history of relapse. There is a need to identify whether maintenance therapy
with rituximab is superior to the current standard of azathioprine or methotrexate for prevention of relapse
following induction with rituximab.
Methods/design: RITAZAREM is an international, multicenter, open-label, randomized controlled trial designed to
demonstrate the superiority of repeated doses of intravenous rituximab compared to daily orally administered azathioprine
as a relapse prevention strategy in patients with AAV with relapsing disease who undergo induction of remission with
rituximab. Patients with AAV will be recruited at the time of relapse and will receive rituximab and glucocorticoid induction
therapy. If the disease is controlled by 4 months, patients will be randomized in a 1:1 ratio to receive rituximab (1000 mg
every 4 months for five doses) or azathioprine (2 mg/kg/day) as maintenance therapy. Patients will be followed for a
minimum of 36 months. The primary outcome is the time to disease relapse. It is estimated that 190 patients will need to
be recruited to ensure that at least 160 are randomized.
Discussion: The RITAZAREM trial will provide the largest trial dataset for the use of rituximab as remission-induction
therapy for patients with AAV comparing two remission-maintenance strategies following induction with rituximab,
and explore whether prolonged B-cell depletion leads to sustained treatment-free remissions after discontinuation of
immunosuppressive therapy.
Trial registration: ClinicalTrials.gov identifier: NCT01697267. Registered on 31 August 2012.
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Background
Granulomatosis with polyangiitis (granulomatous with
polyangiitis (GPA), Wegener’s granulomatosis) and
microscopic polyangiitis (MPA) are two major subgroups
of anti-neutrophil cytoplasmic antibody (ANCA)-associ-
ated vasculitis (AAV). These conditions are character-
ized by leukocyte infiltration of blood vessel walls,
fibrinoid necrosis, and vascular damage, and are usually
associated with the presence of circulating ANCA. In
Europe, AAV has an annual incidence of 19 per million
and a prevalence of 100–250/million [1].
Prior to the availability of effective treatment, AAV
had a mortality of 93% within 2 years, primarily due to
renal and respiratory failure [2]. The introduction of
glucocorticoids (GC) and cyclophosphamide, now
considered conventional immunosuppression for this
disease, has markedly improved survival, inducing re-
mission in approximately 80% of patients at 1 year.
However, relapsing disease is common with over 50% of
patients experiencing a relapse within 5 years [3–5].
Relapses of AAV lead to accrual of damage, both as a
result of disease activity and increased exposure to im-
munosuppressive medications with their associated tox-
icities, especially GC, and at least 25% suffer severe early
or late toxicity from these agents [6]. Strategies that
prevent relapse will reduce consequent morbidity by
reducing organ damage and cumulative drug toxicity.
There is a need for safer therapies that lead to sustained,
and ideally, drug-free remission in patients with relaps-
ing disease in AAV.
B-lymphocytes have been implicated in the pathogen-
esis of AAV. Rituximab is a murine/human chimeric
monoclonal antibody directed against the CD20 antigen
found on the surface of B-lymphocytes, and results in B-
cell depletion. Rituximab has been shown to be nonin-
ferior to cyclophosphamide as an induction agent, and it
is now licensed for remission induction therapy in AAV
[7, 8].
However, only 39% of the patients maintained relapse-
free remission at 18 months following a single course of
rituximab in the RAVE trial, indicating that induction
with rituximab without maintenance therapy is unlikely
to prevent future relapses in the majority of patients [9].
Retrospective analysis of fixed-interval, repeat-dose ther-
apy with rituximab indicated efficacy of maintenance
therapy with rituximab in this subgroup, but a persisting
risk of relapse in longer-term follow-up after rituximab
discontinuation [10–12].
Rationale for the RITAZAREM trial
The MAINRITSAN trial was designed to compare
four cycles of rituximab (500 mg × 2 at 6 months
then 500 mg every 6 months × 3) with maintenance
therapy with azathioprine following induction with
cyclophosphamide in patients with AAV, largely with
patients with newly diagnosed disease [13]. Fixed-
interval rituximab was shown to be more effective in
maintaining remission at 28 months. The MAINRIT-
SAN trial has provided valuable information on the
use of rituximab as a maintenance agent in AAV,
although several important questions remain un-
answered. Firstly, the MAINRITSAN study was
underpowered to assess the effect of repeat-dose ri-
tuximab in the subgroup with the most need of a
remission-maintenance strategy, namely patients with
relapsing disease (only 23 of 115 patients had relaps-
ing disease). Secondly, in many countries rituximab
has now been granted a license for remission-
induction in AAV, and is increasingly being used in
place of cyclophosphamide. The optimal remission
maintenance strategy following rituximab induction
therapy is unknown. Thirdly, relapses do occur
among patients treated with repeatedly-dosed rituxi-
mab, mostly in intervals of 6 more months [11, 12,
14]. Therefore, reducing the interval of repeated
doses of rituximab to 4 months has the potential to
further reduce relapse rates, and aims to maintain
100% B-cell depletion for the entire 24-month treat-
ment phase. Finally, the total dose of rituximab for
maintenance therapy in RITAZAREM is double that
used in MAINRITSAN (5000 mg versus 2500 mg)
which will permit comparison of the safety and
longer-term efficacy of the two dosing regimens.
The RITAZAREM trial will address the question of
the optimal treatment regimen for maintenance of
remission following induction of remission with rituxi-
mab in AAV, and the possibility that prolonged B-cell
depletion using high doses of rituximab, will lead, upon
discontinuation of therapy, to sustained treatment-free
remissions.
Methods/design
RITAZAREM is an international, multicenter, open-
label, randomized controlled trial designed to demon-
strate the superiority of rituximab over azathioprine in
the prevention of relapses in patients with AAV with re-
lapsing disease (see Additional file 1 for the SPIRIT 2013
Checklist). This trial will also assess the risk of relapse
after maintenance therapy is withdrawn at 24 months,
the long-term safety of rituximab administration, and
the optimal maintenance therapy in AAV following in-
duction with rituximab.
The RITAZAREM trial has three phases:
1. An induction phase (months 0 to 4) in which
eligible patients will be enrolled at the time of
disease relapse and all will receive rituximab
(4 weekly doses of 375 mg/m2) and GC
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2. A maintenance phase (months 4 to 24): 4 months
after enrollment, participants who achieve remission
(defined as a Birmingham Vasculitis Activity Score
for Wegener’s granulomatosis (BVAS/WG) ≤1 [15]
and prednisone/prednisolone dose ≤10 mg/day) will
be randomized in 1:1 ratio to receive 1000 mg
rituximab at 4-monthly fixed intervals or daily
azathioprine maintenance therapy (2 mg/kg/day)
3. A treatment-free follow-up period (minimum of 12,
maximum of 24 months)
Randomization and allocation
Enrollment and randomized allocation to treatment arm will
be performed by an Internet-based website (TENELEA)
provided by the Cambridge Clinical Trials Unit.
Blinding
This is an open-label study. Several previous vasculitis
studies that have had major influences on practice and
have stood up to re-examination have been unblinded,
and similar endpoints have been used, with processes
developed in data management to check and manage
potential bias. Blinding would have necessitated the
administration of sham infusions and placebo tablet
medications to all participants, which would have in-
creased the complexity and cost of the trial and exposed
participants to unnecessary interventions. A pragmatic
approach of having the primary endpoint, relapse, inde-
pendently assessed by expert adjudicators blinded to
treatment allocation was decided.
Participants
To be eligible, participants must be aged 15 years and
above and should have a diagnosis of AAV according to
Chapel Hill Consensus Conference definitions [16],
along with a current or historical positive test for pro-
teinase 3/myeloperoxidase anti-neutrophil cytoplasmic
antibody (PR3/MPO ANCA) by enzyme-linked im-
munosorbent assay (ELISA). All patients must have dis-
ease relapse defined by one major or three minor disease
activity items on the BVAS/WG and they must have pre-
viously achieved remission following at least 3 months
of induction therapy, with a combination of GC and an
immunosuppressive agent (cyclophosphamide, rituxi-
mab, methotrexate, or mycophenolate mofetil (MMF)).
Key exclusion criteria include the receipt of any bio-
logical B-cell-depleting agents within the previous
6 months, alemtuzumab, or anti-thymocyte globulin
(ATG) within the last 12 months, or intravenously ad-
ministered immunoglobulin (IVIg), plasma exchange, or
anti-TNF treatment within the last 3 months. Patients
with other multisystem autoimmune disease such as
eosinophilic granulomatous with polyangiitis (eGPA),
systemic lupus erythematosus (SLE), anti-glomerular
basement membrane (GBM) disease or cryoglobulinae-
mic vasculitis, or history of malignancy within the past
5 years are also excluded. Additional file 2 lists the full
inclusion and exclusion criteria for the study.
Participants will be recruited from many centers par-
ticipating in the European Vasculitis Society (EUVAS),
the Vasculitis Clinical Research Consortium (VCRC),
and from centers in Japan, Australia, and New Zealand.
Interventions
See Additional file 3 for figure: RITAZAREM trial flow
chart.
Rituximab arm
Induction phase: rituximab 375 mg/m2/week × 4 doses.
This dose (as opposed to the 2-weekly 1000-mg induction
dose, which has been shown to be equivalent to the four-
dose schedule in retrospective series [17]), was selected
because it is the licensed induction regimen for AAV.
Maintenance phase: 1000 mg of rituximab repeated
every 4 months for a total of five courses. Measureable
B-cells usually return 4 months after a dose of rituxi-
mab, thus an every-4-month dosing interval aims to
maintain 100% B-cell depletion for the entire 24-month
treatment phase. Additionally, in one series of every
6-month fixed dosing of rituximab 90% of relapses oc-
curred in 4–6 months following a dose of rituximab;
therefore, reducing the interval between doses of rituxi-
mab has the potential to further reduce relapse rates
[14]. There is no clear evidence of dose-dependent tox-
icity for rituximab, and thus an every-4-month schedule
was chosen to maximize efficacy.
Control arm
Induction phase: rituximab 375 mg/m2/week × 4 doses.
Maintenance phase: orally administered azathioprine
with a target dose of 2 mg/kg/day (maximum 200 mg/day)
for 24 months. After 24 months, the dose will be reduced
by 50% and it will be completely withdrawn at month 27.
Patients who are intolerant to azathioprine will receive
either methotrexate (administered orally or subcutane-
ously) at a maximum dose of 25 mg/week (if estimated
glomerular filtration rate is >50 ml/min), or MMF at a
maximum dose of 2 g/day (if estimated glomerular filtra-
tion rate (GFR) is ≤50 ml/min).
Concomitant therapy
Glucocorticoids
Induction: since evidence for optimal GC induction dos-
ing in relapsing AAV is lacking, it was decided, to facili-
tate recruitment, to allow investigators to choose from
one of two GC regimens to take into consideration
variability in disease severity and local GC prescribing
practices (Table 1). Patients may receive a maximum
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cumulative dose of 3000 mg intravenously administered
(IV) methylprednisolone, between 14 days prior to en-
rollment and 7 days after enrollment.
Maintenance: an orally administered GC (prednisone/
prednisolone or the equivalent) dose of 10 mg/day or
less is a requirement for randomization at 4 months.
The GC dose is reduced to 5 mg/day by month 6, and is
continued at 5 mg/day until month 16. The GC dose is




Prophylaxis to prevent Pneumocystis (carinii) jiroveci in-
fection and/or to prevent osteoporosis are strongly rec-
ommended but implementation is left to local practice.
Plasma exchange
Plasma exchange can be administered during the induc-
tion period following local practice at the discretion of
the investigator. Rituximab will not be administered
within the 48 h prior to receiving a plasma exchange
treatment.
Treatment of relapse
Time to relapse is the primary endpoint of the study. Pa-
tients experiencing their first minor relapse after
randomization and before month 24 will remain on their
randomized treatment and the dose of orally adminis-
tered prednisone/prednisolone will be increased to
20 mg/day for 1 week decreasing in daily 2.5-mg incre-
ments each week until the dose is back to the dose be-
fore the relapse at which point the patient returns to the
standard dosing schedule. The second minor relapse, or
first major relapse, occurring before month 24, will
result in the patient being withdrawn from protocolized
treatment and the patient will be treated according to
the investigator’s discretion. Any relapse occurring after
the 24-month treatment phase will be treated according
to local best medical practice.
Assessments
Evaluations (including clinical, biochemical, and patient-
reported outcomes) will be performed at months 0, 1.5,
3, 4, 8, 12, 16, 20, 24, 27, 30, 36, and every 6 months
until the last patient has completed 36 months in the
study (see Additional file 4 – SPIRIT figure: RITA-
ZAREM schedule of events). The maximum duration in
the study for any individual is 48 months. Assessments
will also be performed at the time of relapse. Data will
be collected on paper Case Report Forms, and entered




1. Time to disease relapse (either minor or major
relapse), reported at 24 months
Secondary outcomes
1. Proportion of patients who maintain remission at
24 and 48 months
2. Time to a major or second minor relapse
3. Cumulative accrual of damage as measured by the
Combined Damage Assessment (CDA) score [18]
4. Health-related quality of life as measured using
36-item Short Form Health Survey (SF-36), the
European Quality of Life-5 Dimensions (EQ5D), and
Patient Reported Outcomes Measurement Information
System (PROMIS) short forms for fatigue, pain,
physical function, and patient global assessment [19]
5. Cumulative GC exposure
6. Severe adverse event rates and infection (treated
with either intravenously or orally administered
antibiotics) rates
Power calculation
Enrollment will be ongoing until 160 patients are ran-
domized at their 4-month visits. It is anticipated that
190 patients will be required in order to randomize 160
patients. A power of 90% will be achieved under the al-
ternative hypothesis of a hazard ratio of 0.42 at the 5%
significance level with 58 observed relapses. Randomiz-
ing 160 patients will achieve this over the course of the
study assuming a dropout rate up to 5% at 2 years and a
relapse-free rate of 75% and 50% at 4 years in the experi-
mental and control arms, respectively. The hazard ratio
of 0.42 is based on assuming a relapse-free rate of 75%
at 4 years in the rituximab arm versus 50% at 4 years in
the standard treatment arm.
Table 1 Orally administered glucocorticoid (prednisone/





Week <60 kg ≥60 kg <60 kg ≥60 kg
0 50 mg/day 60 mg/day 25 mg/day 30 mg/day
2 35 mg/day 45 mg/day 20 mg/day 25 mg/day
4 25 mg/day 35 mg/day 17.5 mg/day 20 mg/day
6 20 mg/day 25 mg/day 15 mg/day 17.5 mg/day
8 15 mg/day 17.5 mg/day 12.5 mg/day 15 mg/day
10 12.5 mg/day 12.5 mg/day
12 10 mg/day 10 mg/day
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Analyses
A statistical analysis plan, separate to the study protocol,
will be finalized prior to any analyses being performed.
The primary intention-to-treat analysis will be based on
a Cox proportional hazard model. There will be a closed
testing procedure. Hazard ratios and 95% confidence in-
tervals will be reported. First, the null hypothesis will be
for a hazard ratio of 1 at all time points. If this is
rejected at a 5% level then two further subhypotheses
will be examined using time-varying covariates:
1. A hazard ratio of 1 up to 24 months post
randomization (i.e. during treatment)
2. A hazard ratio of 1 after 24 months post
randomization (i.e. post treatment)
Funding, sponsor, and committee oversight
RITAZAREM is funded by grants from Arthritis
Research UK and Roche/Genentech. The Vasculitis
Clinical Research Consortium (VCRC) (U54 AR057319
and U01 AR5187404) is part of the Rare Diseases Clin-
ical Research Network (RDCRN), an initiative of the
Office of Rare Diseases Research (ORDR), National
Center for Advancing Translational Science (NCATS).
The VCRC is funded through collaboration between
NCATS, and the National Institute of Arthritis and
Musculoskeletal and Skin Diseases, and has received
funding from the National Center for Research Re-
sources (U54 RR019497). The primary sponsor is Cam-
bridge University Hospitals NHS Foundation Trust and
there are collaboration and data-sharing agreements
with the University of Pennsylvania and the University
of Miyazaki Hospital and Okayama University Graduate
School of Medicine, Dentistry, and Pharmaceutical Sci-
ences in Japan. A NIAMS Data and Safety Monitoring
Board (DSMB) will provide oversight of this study. This
is a standing DSMB that provides such oversight for all
VCRC research studies, including randomized trials. The
DSMB will meet at least every 6 months to discuss the
study progress and more frequently, if needed. The Trial
Steering Committee will provide overall supervision of
the study on behalf of the principal funder, Arthritis Re-
search UK. The Trial Steering Committee will monitor
the progress of the study and maximize the chances of
completing the study within the agreed time scale and
budget. The Trial Management Committee is respon-
sible for the design, conduct and overall management of
the study. Cambridge Clinical Trials Unit has provided
support in all phases of trial design, conduct, and man-
agement for this trial.
Patient participation
The design of the study was presented at multiple local,
national, and international meetings with patient attendees
with positive review and input received from patients with
AAV. The Patient Information Sheet was reviewed and
commented upon by a patient panel prior to submission to
the Ethics Committee.
Discussion
It is becoming increasingly clear that patients with AAV
with relapsing disease need different treatment strategies
compared to patients with nonrelapsing disease. RITA-
ZAREM is the largest clinical trial recruiting only the
subgroup of patients with relapsing AAV.
The RITAZAREM trial will add to our knowledge on
the use of rituximab both as an induction and a main-
tenance therapy in this particular patient population.
This trial will also be the largest study to examine the
outcome of induction with rituximab at 4 months in pa-
tients with relapsing AAV.
The MAINRITSAN study has shown that fixed-
interval re-dosing of rituximab is effective in patients
with AAV with new or relapsing disease but the RITA-
ZAREM trial will also answer the following specific
questions:
 Is fixed-interval rituximab re-dosing therapy
superior to azathioprine in maintaining remission
following rituximab induction in relapsing patients?
 Does a higher rituximab dose confer long-term
benefit after discontinuation of therapy, without
significant drug-related toxicity?
Data generated from the RITAZAREM study will
compliment the already-available results of the MAIN-
RITSAN trial [13] and published cohort studies [11, 12,
14]. RITAZAREM is an example of an academic-led
clinical trial in a rare disease, facilitated by highly collab-
orative work of established regional vasculitis networks
in Europe, North America, Japan, and Australia/New
Zealand. It also demonstrates collaboration between aca-
demia and the pharmaceutical industry and continues
the repurposing of a drug originally developed for
lymphoma but subsequently licensed for the auto-
immune disease rheumatoid arthritis.
Trial status
Enrollment was completed on 21 November 2016, and
thus randomization will be complete by the end of
March 2017. The primary endpoint will be reported in
2019, and the final trial report in 2020.
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Gopaluni et al. Trials  (2017) 18:112 Page 5 of 6
Additional file 2: Inclusion and exclusion criteria for RITAZAREM trial;
full list of enrollment requirements. (DOC 34 kb)
Additional file 3: RITAZAREM trial flow chart; RITAZAREM study schema.
(DOC 68 kb)
Additional file 4: SPIRIT figure: RITAZAREM schedule of events;
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